» Articles » PMID: 14751160

The Prognostic Significance of Thrombocytosis in Epithelial Ovarian Carcinoma

Overview
Journal Gynecol Oncol
Date 2004 Jan 31
PMID 14751160
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to determine the incidence of thrombocytosis in epithelial ovarian carcinoma and examine associations with clinico-pathologic features. Thrombocytosis (platelet counts >400 x 10(9)/l) has been identified as a poor prognostic factor in many cancers. Platelet-secreted factors may contribute to metastasis, invasion, and primary tumor growth.

Methods: One hundred eighty-three patients with invasive epithelial ovarian or primary peritoneal carcinomas were identified between January 1996 and December 2000. Records were retrospectively reviewed and data analyzed using chi(2), Student's t test, and Cox proportional hazards model; survival was analyzed by the method of Kaplan and Meier.

Results: Forty-one of 183 (22.4%) patients had thrombocytosis at primary diagnosis. Patients with preoperative thrombocytosis were found to have greater elevations of CA-125 (P = 0.026), more advanced stage disease (P = 0.016), higher grade tumors (P = 0.010), more frequent lymph node metastases (P = 0.018), and greater volume of ascites (P < 0.0001). One hundred sixty of 183 (87.4%) patients achieved optimal cytoreduction; patients with thrombocytosis demonstrated a greater likelihood of suboptimal resection (residual disease >1 cm; 19/41 vs. 4/142 in patients without thrombocytosis, P < 0.0001). Patients with thrombocytosis had a shorter disease-free interval (12 vs. 34 months, P < 0.0001) and overall survival (28 vs. 79 months, P < 0.0001). On multivariate analysis, thrombocytosis retained significance as a poor prognostic indicator in patients with stage III and IVA disease (P = 0.04).

Conclusions: Thrombocytosis is a frequent preoperative finding in ovarian and peritoneal carcinomas and may be a marker of aggressive tumor biology.

Citing Articles

Development and Internal Validation of Nomograms for Survival of Advanced Epithelial Ovarian Cancer Based on Established Prognostic Factors and Hematologic Parameters.

Said S, IntHout J, den Ouden J, Walraven J, van der Aa M, de Hullu J J Clin Med. 2024; 13(10).

PMID: 38792332 PMC: 11122536. DOI: 10.3390/jcm13102789.


Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.

Pergialiotis V, Vogiatzi Vokotopoulou L, Vlachos D, Liontos M, Kontomanolis E, Thomakos N Eur J Obstet Gynecol Reprod Biol X. 2024; 22:100312.

PMID: 38745890 PMC: 11091518. DOI: 10.1016/j.eurox.2024.100312.


Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer.

Kim M, Baek S, Noh J, Shim J, Kang J, Jeong S Front Oncol. 2022; 12:926878.

PMID: 36158646 PMC: 9493080. DOI: 10.3389/fonc.2022.926878.


Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: A systematic review and meta-analysis.

Xia S, Wu W, Yu L, Ma L, Chen S, Wang H Medicine (Baltimore). 2022; 101(35):e30275.

PMID: 36107503 PMC: 9439792. DOI: 10.1097/MD.0000000000030275.


Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Liberto J, Chen S, Shih I, Wang T, Wang T, Pisanic 2nd T Cancers (Basel). 2022; 14(12).

PMID: 35740550 PMC: 9221480. DOI: 10.3390/cancers14122885.